Advertisement
Advertisement
U.S. markets close in 3 hours 23 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Codexis, Inc. (4QK.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
5.91-0.46 (-7.28%)
As of 06:00PM CEST. Market open.
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close6.37
Open6.43
Bid5.95 x 89300
Ask6.16 x 86300
Day's Range5.91 - 6.43
52 Week Range5.80 - 35.80
Volume200
Avg. Volume3
Market Cap391.612M
Beta (5Y Monthly)1.57
PE Ratio (TTM)N/A
EPS (TTM)-0.30
Earnings DateNov 02, 2022 - Nov 07, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est29.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for 4QK.F

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      Codexis Announces Appointment of Rahul Singhvi, Sc.D., to Board of Directors

      REDWOOD CITY, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced the appointment of Rahul Singhvi, Sc.D., to its Board of Directors. Dr. Singhvi is a biotechnology industry veteran with more than three decades of research and development, operations and commercialization expertise across his time with Takeda Pharmaceutical Co., Novavax, Inc. and Merck & Co., Inc. He currently serv

    • GlobeNewswire

      Codexis Announces Appointment of Kevin Norrett as Chief Operating Officer

      REDWOOD CITY, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced the appointment of Kevin Norrett as Chief Operating Officer (COO), effective immediately. In this role, Mr. Norrett is responsible for driving the Company’s corporate growth strategy, business development and operational activities and reports directly to Dr. Stephen Dilly, President and CEO of Codexis. “Kevin brings

    • GlobeNewswire

      Codexis’ 2022 Protein Engineering Forum Showcases Recent Industry Success and Emerging Innovations in the Field

      REDWOOD CITY, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced the recent hosting of its in-person Protein Engineering Forum from September 12-13, 2022 in San Francisco, California. This year, the forum brought over 100 top scientists and innovators together to share insights and recent technological advancements across genomics, nucleic acid synthesis and synthetic biology. Ov

    Advertisement
    Advertisement